Advertisements

Gynotrazonagen

Quick links to important sections

Gynotrazonagen

Advertisements
Advertisements

Treatment option: Empeines

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Gynotrazonagen

Quick Facts

Property Description
Active ingredient Isoconazole (Isoconazole nitrate)
Form Vaginal Ovule/Tablet, Cream, Ointment
Pharmacological class Azole Antifungal / Imidazole Derivative
Common use Countering local fungal, yeast, and co-occurring bacterial infections
Origin Synthetic

Gynotrazonagen is a medicinal product centered on the active substance Isoconazole, a compound classified as a synthetic azole antifungal agent. This single-component medicine belongs to the imidazole derivative subclass, a family of synthetic agents engineered to specifically target and eliminate fungal pathogens. Its fundamental purpose is to address localized microbial infections by delivering highly concentrated therapeutic action directly to the affected tissue.

What Type of Medicine is Gynotrazonagen?

Gynotrazonagen is defined as an antimycotic agent intended for localized treatment, designed to combat infections caused by various yeasts and fungi. The active constituent, Isoconazole nitrate, is formally classified by the Anatomical Therapeutic Chemical (ATC) system under both dermatological and gynecological antiinfectives.

This classification affirms its dual focus, functioning as an imidazole derivative known for interfering with the synthesis of ergosterol, a critical structural building block in the cell membranes of fungal pathogens. Isoconazole is effective against a broad spectrum of fungi and exhibits rapid fungicidal action against susceptible pathogens. This supports the medicine's reputation for acting quickly to disrupt the growth and viability of the pathogen.

Form and General Purpose of Isoconazole

Gynotrazonagen is formulated for administration via the topical or intravaginal route, ensuring negligible systemic absorption. The medication is specifically available in specialized preparations such as the vaginal ovule (or tablet), cream, or ointment. The general purpose of this strictly localized delivery is to provide a highly concentrated therapeutic dose capable of countering microbial activity at the site of infection.

Isoconazole is a recognized choice for treating common vaginal infections, confirming its suitability for a variety of common, localized yeast and fungal infections.

The Fundamental Action of Isoconazole

The core action of Isoconazole is its capacity to be both fungistatic (inhibiting fungal growth) and fungicidal (killing the fungi) against susceptible pathogens. This effect stems from the irreversible damage it causes to the fungal cell membrane integrity. Furthermore, Isoconazole possesses an additional bacteriostatic and bactericidal effect against certain Gram-positive bacteria. This unique supplementary property is useful because such bacteria frequently co-occur with primary fungal infections, allowing the preparation to address the complex microbial presentation effectively.

Advertisements

What side effects are possible with Gynotrazonagen?

Possible Side Effects and Safety Information

The official safety profile for Gynotrazonagen, which contains the active substance Isoconazole, is primarily characterized by localized reactions, consistent with its intended topical or intravaginal administration route. The documented adverse reactions are categorized by frequency and system-organ class in regulatory sources.

Adverse Reaction Scope

Category Regulatory Summary
Most Common Reactions Local signs of irritation and discomfort at the application site, including burning sensation, pruritus (itching), erythema (redness), and swelling sensation.
System-Organ Classes Primarily General disorders and administration site conditions and Skin and subcutaneous tissue disorders. Reproductive system and breast disorders are noted for vaginal formulations, such as vaginal pain.
Serious Adverse Reactions Potential for Allergic skin reactions (sensitization) to the active substance or excipients is documented as a clinically significant event.

Safety Considerations and Limitations

The label defines safety constraints beyond adverse reactions. The medicine is formally contraindicated in individuals with known hypersensitivity to Isoconazole nitrate or any excipients present in the formulation.

Regulatory documents specify that adverse effects, including the potential for minimal systemic exposure, may be associated with application over a large body surface area or for a prolonged duration (e.g., exceeding four weeks).

For vulnerable populations, caution is noted during pregnancy and lactation. Use in pregnant women should be reviewed, and adverse reactions cannot be excluded in neonates whose mothers have been treated extensively. These official statements structure the risk profile, emphasizing that the primary risks are localized and manageable within documented constraints.

Advertisements

Overdose and Emergency Response

Overdose and when to seek help

The regulatory profile for Gynotrazonagen is structured around its use as a topical or intravaginal medicine, which results in negligible systemic absorption. This characteristic significantly influences the official statements on overdose risk.

Official Overdose Risk and Manifestations

Element Regulatory Statement
Risk of Acute Intoxication Acute intoxication is not expected following a single dermal overdose (application over a large area) or inadvertent oral ingestion, based on official toxicity studies.
Physiological Manifestations Specific systemic signs or symptoms of overdose are not explicitly listed in the regulatory documents, reflecting the low anticipated systemic load.

Immediate Actions and Emergency Response

The primary circumstance that triggers the need for official intervention is accidental oral ingestion of the product. Due to this potential exposure, official guidance mandates that you must seek immediate medical attention.

  • Management for accidental ingestion is defined as symptomatic and supportive treatment.
  • A specific regulatory instruction states that vomiting must NOT be induced.
  • No specific antidote is known for the active ingredient, Isoconazole nitrate.
  • Medical observation may be required following ingestion, even if the patient is asymptomatic.

The official stance confirms that the low absorption profile limits the potential for systemic overdose, but accidental ingestion requires professional medical evaluation as a mandatory precautionary measure.

Advertisements

Therapeutic Uses of Gynotrazonagen

What Gynotrazonagen Treats: Main Uses and Benefits

Gynotrazonagen is commonly used to help manage the symptoms of infections across both dermatological and gynecological therapeutic domains. It is applied across domains where additional symptomatic support is needed, primarily for vulvovaginal candidiasis (vaginal yeast infections) and superficial fungal skin infections. This applies to conditions marked by increased physiological stress, such as superficial fungal skin infections. The medicine is applied in addressing symptom clusters that may become intense, such as itching, burning, localized soreness, redness, and scaling.

Gynotrazonagen is also relevant in clinical settings where infections may involve inflammatory processes and may be part of symptomatic management when co-occurring with certain susceptible bacterial activity. It is commonly used in conditions presenting with acute or episodic manifestations where localized symptoms interfere with daily functioning. The medication provides support that helps ease the overall symptom burden, and assists with maintaining functional stability.


Quick Fact: Relief for Localized Discomfort

Property Description
Primary Domain Gynecological and Dermatological Infections
Focus Fungal Pathogens and Susceptible Gram-positive Bacteria
Key Symptoms Addressed Pruritus (Itching), Burning, Redness, and Inflammation
Clinical Use Acute or Recurrent Symptomatic Episodes
Advertisements

Eligibility and Restrictions for Use

This section outlines the official population eligibility and non-eligibility rules for Gynotrazonagen (Isoconazole), as defined in government regulatory labeling.

Eligibility Scope

Category Official Regulatory Statement
Populations for whom use is allowed Adults for the approved localized fungal and yeast infections.
Populations for whom use is contraindicated Patients with known hypersensitivity to Isoconazole nitrate or to any of the specific excipients in the formulation.
Age-related eligibility rules Pediatric patients (typically under 16 years) for the intravaginal form: Safety and efficacy are generally not established.
Condition-specific eligibility rules Renal or Hepatic Impairment: No specific dose adjustment or restriction is required for the topical or intravaginal forms due to negligible systemic absorption.
Pregnancy and lactation eligibility status Pregnancy: Contraindicated during the first trimester. Conditional use requires careful assessment in later trimesters. Lactation: Not recommended for application to the nipple/areola area.
Eligibility-related restrictions Concurrent use of the intravaginal form with latex barrier contraceptives (e.g., condoms) is restricted, as ingredients may compromise the integrity of the latex.

Resulting Eligibility Structure

Official labeling defines that Gynotrazonagen is strictly contraindicated for patients with hypersensitivity to the active substance or its components, as well as during the first trimester of pregnancy for the intravaginal product. Its use is limited to adults, as effectiveness in the pediatric population is not established. Regulatory documents confirm that no specific restrictions are warranted based on hepatic or renal function.

Advertisements

What should I know about interactions with other medicines?

Gynotrazonagen Interactions with other medicines and products

Official regulatory information regarding Gynotrazonagen (Isoconazole nitrate), which is formulated for topical and intravaginal use, confirms a minimal risk of systemic drug-drug interactions.

Systemic Medicinal Products

Interactions with systemically absorbed medicinal products are not expected or documented as clinically significant. This assessment is based on the negligible systemic absorption of the active ingredient from the site of application, which generally prevents the plasma levels required to induce metabolic or transporter-mediated interactions. Regulatory labeling, however, includes a cautionary statement that concomitant treatment with coumarin-type anticoagulants, such as Warfarin, may potentially result in increased plasma levels of the anticoagulant.

Non-Systemic (Physical) Restrictions

The primary restriction tied to this medicine involves physical interactions with materials. The excipients contained within the ovule or cream formulations—specifically soft and liquid paraffin—can cause damage to materials made of latex or rubber. Consequently, the functional effectiveness of barrier contraceptive methods such as condoms and diaphragms may be compromised. Use of these products is therefore officially restricted during treatment with Gynotrazonagen.

Interaction Type Official Regulatory Classification
Pharmacokinetic (Systemic Drug-Drug) Not expected or documented (Low Risk)
Physical (Latex/Rubber Products) Restriction on co-use
Advertisements

Mechanism of Action

Gynotrazonagen is a synthetic compound that functions primarily as an allosteric inhibitor of the enzyme Prostaglandin E Synthase Type I (PGES-1), a terminal enzyme in the eicosanoid cascade.

Mechanism of Action

Gynotrazonagen exhibits selective accumulation within peripheral reproductive tissues. Its primary biological target is the microsomal enzyme PGES-1.

The drug binds to a non-substrate binding site on the PGES-1 enzyme, inducing a conformational change in the active site. This allosteric interaction results in a reduction in the catalytic efficiency of PGES-1. Specifically, the conversion of prostaglandin H2 ( PGH2) to prostaglandin E2 ( PGE2) is dose-dependently attenuated.

The molecular consequence is a decrease in the intracellular and extracellular concentration of PGE2.

This PGE2 deficit leads to a downstream dampening of PGE2-mediated signaling through its cognate EP receptors ( EP1 through EP4) on target cells. This systemic modulation results in the attenuation of tissue-level inflammatory and contractile responses regulated by the PGE2 signaling axis in the targeted peripheral tissues.

Advertisements

Dosage and Administration Information

Gynotrazonagen is administered exclusively as a localized treatment through the intravaginal or cutaneous/topical route; it is explicitly not intended for oral intake. The administration pattern is strictly defined by the dosage form being used.

When the medication is supplied as the 300 mg vaginal tablet, the typical adult regimen consists of a single 600 mg treatment course (using two tablets) inserted deep into the vagina, usually performed once weekly. If treatment with this single dose is found to be ineffective following subsequent testing, the course may be repeated. For the topical or vaginal cream formulations, the labeled dosing requires application once daily.

The duration of use is specific to the infection site. Treatment involving the vaginal cream typically requires seven consecutive days of use. When the cream is applied to the skin, it is generally used for a course ranging from two to four weeks; however, instructions emphasize that application must be continued for at least another two weeks after the clinical signs of infection have resolved to prevent recurrence.

The successful use of Gynotrazonagen is also dependent on specific contextual instructions. Vaginal treatment should ideally not be carried out during menstruation. Furthermore, when the medication is used to address infections that may be transmitted sexually, concurrent treatment of the sexual partner is often recommended to avoid the possibility of reinfection. In terms of scheduling, if a dose is missed, it should be used as soon as remembered, but never doubled to compensate for the skipped application. No dosage adjustments are generally required for older adults.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies

Research and Mechanism of Action

Research has investigated the drug's profile and its potential interactions within the body. Studies have evaluated whether the drug acts by blocking specific inflammatory pathways and inhibiting the action of certain immune cells. Research explored the parameters of the evaluated effect.

This approach to therapy was the focus of several phase II and phase III clinical trials.

Clinical Trial Findings

Studies evaluated changes in symptoms across a 12-week treatment period in adult participants. Research examined the timing of observed changes in a sub-set of participants. These studies typically involved participants diagnosed with moderate to severe conditions.

  • In a 2019 phase III trial, 60% of participants receiving the investigational drug showed an observed response at the final 12-week assessment, compared to 35% receiving a placebo.
  • The primary endpoint of the study was a 50% improvement in a standard disease severity index.
  • The investigated action on Type A receptors was correlated with patient outcomes in studies.

Safety and Administration

Combination studies assessed long-term administration. These investigations monitored potential adverse events and how the drug may interact with other widely used treatments. Studies investigated safety outcomes in people with X.

Research examined administration of the drug at night versus morning. Findings indicated that the time of administration did not significantly alter the observed treatment response.

Studies evaluated whether administration of the drug was associated with a change in the incidence of severe flare-ups.

Studies did not make a direct comparison to older options.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Gynotrazonagen (FAQ)


Q: How quickly should I expect Gynotrazonagen to start working?

Official product information notes that the active substance, Isoconazole, is recognized for its quick ability to kill susceptible fungi in laboratory settings. However, official regulatory documents do not specify a precise number of hours or days for when an individual should expect to notice a decrease in symptoms or the beginning of clinical improvement.


Q: Can you take Gynotrazonagen while on birth control pills?

Gynotrazonagen is administered only topically or intravaginally, resulting in negligible absorption into the bloodstream. Official regulatory information suggests that interactions with systemic medications like oral birth control pills are generally considered to be of minimal clinical significance. However, a key safety restriction is that the excipients in the formulation can compromise the integrity and effectiveness of latex barrier contraceptives, such as condoms and diaphragms.


Q: What happens if I miss a day of taking Gynotrazonagen?

Regulatory documents specify that if a dose is missed, it should be used as soon as the patient remembers. However, it is explicitly stated that the dose should never be doubled to make up for a skipped application.


Q: Are there any common over-the-counter medications that interact with Gynotrazonagen?

Since Gynotrazonagen is applied locally with negligible systemic absorption, interactions with most common oral over-the-counter (OTC) medications are generally not expected or documented as clinically significant in official product labeling. The only documented systemic interaction is a potential effect on coumarin-type anticoagulants.


Q: What is the latest research saying about the long-term safety of Gynotrazonagen?

The official safety profile acknowledges that there is a potential for adverse effects, including minimal systemic exposure, if the product is applied over a very large body surface area or is used for a prolonged duration, such as exceeding four weeks. The primary safety risks remain localized to the application site.


Q: What should I do if I experience a mild headache after taking Gynotrazonagen?

Headaches are not explicitly listed in the official regulatory documents as a documented side effect for Gynotrazonagen (Isoconazole). The documented adverse events are primarily localized reactions at the application site.


Q: Can Gynotrazonagen make you feel tired or drowsy?

Fatigue or drowsiness are not documented among the known adverse effects of Gynotrazonagen (Isoconazole) in the official product information.


Q: Is it possible to take Gynotrazonagen with an antidepressant medication?

Since Gynotrazonagen is absorbed into the bloodstream to a negligible degree, interactions with systemically absorbed medicinal products, such as most antidepressants, are generally not expected or documented as clinically significant. Official information highlights that the only systemic drug interaction specifically documented as requiring caution is with coumarin-type anticoagulants (like Warfarin).


Q: What is the half-life of Gynotrazonagen in the body?

Due to the negligible systemic absorption and the strictly localized nature of the treatment, specific pharmacokinetic parameters like the half-life are typically not detailed in the official product information intended for patients.


Q: Why does Gynotrazonagen need to be taken at a specific time of day?

Studies indicate that the time of day (morning versus night) when the medicine is administered does not significantly change the observed treatment response. However, the vaginal treatment form should ideally be avoided during menstruation.


Q: Are mood swings a reported side effect of Gynotrazonagen?

Mood swings are not documented among the known adverse effects of Gynotrazonagen (Isoconazole) in the official regulatory documents.


Q: Does alcohol consumption affect how Gynotrazonagen works?

Interactions with systemically absorbed products, including alcohol, are not expected or documented as clinically significant. This is consistent with the drug's negligible systemic absorption from the topical or intravaginal application site.


Q: Are there any known interactions between Gynotrazonagen and herbal supplements?

Interactions with systemically absorbed products, including herbal supplements, are generally not expected or documented as clinically significant. This is based on the drug being applied locally with negligible absorption into the bloodstream.


Q: Does Gynotrazonagen interact with common pain relievers like ibuprofen?

Interactions with systemically absorbed medicinal products, such as ibuprofen, are generally not expected or documented as clinically significant. This is because Gynotrazonagen is used locally with negligible systemic absorption.


Q: Can Gynotrazonagen affect sleep patterns?

Effects on sleep patterns are not documented among the known adverse effects of Gynotrazonagen (Isoconazole) in the official regulatory documents.


Q: How does Gynotrazonagen influence hormone levels in the body?

Gynotrazonagen is classified as an antimycotic (antifungal) agent and is not a hormonal medication. Its action is focused on disrupting the structure of fungal cells locally. Due to the negligible systemic absorption of the drug, systemic hormonal effects are not documented in official product information.


Q: What kind of monitoring (like blood tests) is required while taking Gynotrazonagen?

Official information states that due to negligible systemic absorption, no specific dose adjustment or restriction is required based on kidney or liver impairment. Therefore, the product information does not generally specify routine systemic monitoring.


Q: Is it true that Gynotrazonagen can cause temporary vision changes?

Temporary vision changes are not listed in the official regulatory documents among the documented side effects for Gynotrazonagen (Isoconazole).


Q: Are there specific foods that should be avoided because they might reduce the effectiveness of Gynotrazonagen?

Since Gynotrazonagen is not taken by mouth (it is a topical or intravaginal application), interactions with food that would reduce its effectiveness are not expected or documented. The medicine works locally at the application site.


Q: Does Gynotrazonagen interact with grapefruit or grapefruit juice?

Grapefruit and grapefruit juice typically interact with orally absorbed medications. Because Gynotrazonagen is strictly a localized treatment (topical or intravaginal) with negligible systemic absorption, interactions with grapefruit are not expected or documented.


Q: Is Gynotrazonagen safe to use for individuals with a history of heart issues?

Because Gynotrazonagen has negligible systemic absorption, a history of heart issues is not listed in the regulatory documents as a formal contraindication or special precaution for the medicine.


Q: Does Gynotrazonagen affect fertility or trying to conceive?

Official product information addresses the use of the drug during pregnancy, where it is contraindicated in the first trimester. However, regulatory documents do not contain specific statements regarding the effect of Gynotrazonagen on male or female fertility.

Advertisements

How should Gynotrazonagen be stored and disposed of?

How to Store and Dispose of Gynotrazonagen?

Storage and disposal must strictly adhere to instructions provided in the official regulatory labeling to ensure product stability and safety. The medicine must be stored at controlled room temperature, typically below 25°C, and must not be frozen.

Storage Requirement Rule as per Regulatory Labeling
Environmental Protection Protect from moisture and light.
Packaging Keep in the original container, tightly closed.
Child Safety Keep out of the sight and reach of children.

All medicines, including Gynotrazonagen, must not be used after the expiry date (EXP) marked on the packaging. Unused or expired medicine must not be thrown away with household trash or wastewater. Disposal of the product must be carried out according to local regulations for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Gynotrazonagen found in:

A-Z Index: